Evidence map›Paper›PMID 41000060›Full record

ArticleJournal of mass spectrometry : JMS2025

Mass Spectrometric Assessment of the Reactivity and Target Sites of 3-Aminopropanal and 3-Aminopropanal-Released Acrolein in Peptides and Proteins.

Michaela Rašková, Vlastimil Dorčák, Jan Vacek, Marek Šebela

Abstract read
In one paragraph

Article in Journal of mass spectrometry : JMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michaela RaškováDepartment of Biochemistry, Faculty of Science, Palacký University, Olomouc, Czech Republic.
Vlastimil DorčákDepartment of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
Jan VacekDepartment of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
Marek ŠebelaDepartment of Biochemistry, Faculty of Science, Palacký University, Olomouc, Czech Republic.ORCID https://orcid.org/0000-0001-9835-1375

Funding

Univerzita Palackého v Olomouci IGA_PrF_2023_022
6 · The paper itself

Abstract

Living cells are frequently exposed to aldehydes, as these compounds are produced during metabolism, found in natural dietary sources, and present as contaminants, drugs, and pollutants. For instance, acrolein is well-known as a toxic pollutant, but is also produced in the metabolism of polyamines, threonine, and polyunsaturated fatty acids. Another aldehyde, 3-aminopropanal, is a byproduct of polyamine oxidation, and its cytotoxicity has been implicated in various diseases, especially those involving oxidative stress and cellular damage. 3-Aminopropanal can readily convert to acrolein through ammonia elimination. Our objective was to compare the reactivity of these two compounds toward biomolecules. Amino acids such as cysteine and lysine, along with model peptides and proteins, were reacted with an excess of each compound. The reacted molecules were analyzed by MALDI-TOF mass spectrometry to assess the extent of modification by examining the difference in molecular mass. Modified peptides, including those obtained by enzymatic digestion of the reacted model proteins, were subjected to tandem mass spectrometry to identify modification sites and determine the structure of the modified amino acids. The most characteristic modifications were Michael addition to cysteine and Schiff base formation with lysine, consistent with known acrolein-induced protein modifications. Compared to acrolein, 3-aminopropanal exhibited substantially reduced reactivity, though it generally targeted the same sites. These results represent the first experimental characterization of 3-aminopropanal-induced protein modifications at the molecular level, and support the notion that 3-aminopropanal is converted to acrolein, which acts as the modifying agent.

Indexed as

AcroleinPeptidesProteinsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAnimalsCysteineLysineTandem Mass SpectrometryAcroleinCysteineLysinePeptidesProteins3‐aminopropanalacroleinMichael adductmodificationSchiff base

Identifiers

PMID41000060
PMCPMC12464801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.